DisEMBARK? FDA Questions Accelerated Approval Impact On Sarepta’s Fully Enrolled Clinical Trial

 
• By Sue Sutter
  
Gangplank
US FDA questions whether US study subjects will leave the EMBARK trial if SRP-9001 receives accelerated approval. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers